These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

647 related items for PubMed ID: 12915663

  • 1. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
    Guerin M, Le Goff W, Frisdal E, Schneider S, Milosavljevic D, Bruckert E, Chapman MJ.
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
    Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ.
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
    [Abstract] [Full Text] [Related]

  • 4. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D, Griglio S, Le Naour G, Chapman MJ.
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state.
    Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ.
    J Lipid Res; 2002 Oct; 43(10):1652-60. PubMed ID: 12364549
    [Abstract] [Full Text] [Related]

  • 7. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG, Patel ST, Falko JM, Newman HA, Hill DS.
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [Abstract] [Full Text] [Related]

  • 8. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia.
    Guerin M, Egger P, Le Goff W, Soudant C, Dupuis R, Chapman MJ.
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4991-5000. PubMed ID: 12414863
    [Abstract] [Full Text] [Related]

  • 9. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN.
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [Abstract] [Full Text] [Related]

  • 10. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.
    Guérin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ.
    Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):763-72. PubMed ID: 8640404
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
    Le Goff W, Guerin M, Chapman MJ.
    Pharmacol Ther; 2004 Jan; 101(1):17-38. PubMed ID: 14729390
    [Abstract] [Full Text] [Related]

  • 12. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH.
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
    Bruckert E, Dejager S, Chapman MJ.
    Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
    [Abstract] [Full Text] [Related]

  • 15. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
    Chapman MJ, Guérin M, Bruckert E.
    Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339
    [Abstract] [Full Text] [Related]

  • 16. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
    Tamai T, Nakai T, Yamada S, Kobayashi T, Hayashi T, Kutsumi Y, Takeda R.
    Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
    [Abstract] [Full Text] [Related]

  • 17. Etofibrate increases binding of low and high density lipoprotein to human platelets of patients with type II hyperlipoproteinemia.
    Virgolini I, Koller E, Li S, Yang Q, Banyai M, Rauscha F, Pidlich J, Pirker W, Sinzinger H.
    Atherosclerosis; 1993 Sep; 102(2):217-26. PubMed ID: 8251008
    [Abstract] [Full Text] [Related]

  • 18. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V, Souki A, Cano-Ponce C, Bermúdez-Arias F, Mengual-Moreno E, Leal-Gonzalez E, Lemus-Antepaz M, de Bravo MC, de Díaz AA, de Pirela NL, Cano-Peñaloza R, Puche-Medina G, Arraiz N, Reyna-Villazmil N, Contreras F, Israili ZH, Valasco M.
    Am J Ther; 2007 Sep; 14(2):213-20. PubMed ID: 17414592
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.